2. Academic Validation
  3. Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy

Inhibition of Alternative Cancer Cell Metabolism of EGFR Mutated Non-Small Cell Lung Cancer Serves as a Potential Therapeutic Strategy

  • Cancers (Basel). 2020 Jan 10;12(1):181. doi: 10.3390/cancers12010181.
Chung-Yu Huang 1 2,  Li-Han Hsu 1 3 4,  Chung-Yeh Chen 2,  Gee-Chen Chang 4 5 6,  Hui-Wen Chang 1 2 7,  Yi-Mei Hung 8,  Ko-Jiunn Liu 2 8 9,  Shu-Huei Kao 1 2 7
Affiliations

Affiliations

  • 1 Ph.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • 2 School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • 3 Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei 11259, Taiwan.
  • 4 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
  • 5 Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
  • 6 Institute of Biomedical Sciences, National Chung-Hsing University, Taichung 40227, Taiwan.
  • 7 Department of Medical Laboratory, Taipei Medical University Hospital, Taipei 11031, Taiwan.
  • 8 National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli 35035, Taiwan.
  • 9 Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan 70101, Taiwan.
PMID: 31936895 DOI: 10.3390/cancers12010181
Abstract

Targeted therapy is an efficient treatment for patients with epidermal growth factor receptor (EGFR) mutations in non-small cell lung Cancer (NSCLC). Therapeutic resistance invariably occurs in NSCLC patients. Many studies have focused on drug resistance mechanisms, but only a few have addressed the metabolic flexibility in drug-resistant NSCLC. In the present study, we found that during the developing resistance to tyrosine kinase inhibitor (TKI), TKI-resistant NSCLC cells acquired metabolic flexibility in that they switched from dependence on glycolysis to Oxidative Phosphorylation by substantially increasing the activity of the mitochondria. Concurrently, we found the predominant expression of Monocarboxylate Transporter 1 (MCT-1) in the TKI-resistant NSCLC cells was strongly increased in those cells that oxidized lactate. Thus, we hypothesized that inhibiting MCT-1 could represent a novel treatment strategy. We treated cells with the MCT-1 inhibitor AZD3965. We found a significant decrease in cell proliferation and cell motility in TKI-sensitive and TKI-resistant cells. Taken together, these results demonstrated that gefitinib-resistant NSCLC cells harbored higher mitochondrial bioenergetics and MCT-1 expression. These results implied that targeting mitochondrial Oxidative Phosphorylation proteins or MCT-1 could serve as potential treatments for both TKI-sensitive and -resistant non-small cell lung Cancer.

Keywords

EGFR; NSCLC; alternative metabolism; gefitinib-resistant; monocarboxylate transporter 1.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z